These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 16834832

  • 1. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M.
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 3. Superiority of escitalopram to paroxetine in the treatment of depression.
    Kasper S, Baldwin DS, Larsson Lönn S, Boulenger JP.
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
    [Abstract] [Full Text] [Related]

  • 4. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 5. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.
    Boulenger JP, Hermes A, Huusom AK, Weiller E.
    Curr Med Res Opin; 2010 Mar; 26(3):605-14. PubMed ID: 20067433
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L, Andersen HF, Reines EH.
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [Abstract] [Full Text] [Related]

  • 7. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC.
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [Abstract] [Full Text] [Related]

  • 8. The effect of escitalopram on sleep problems in depressed patients.
    Lader M, Andersen HF, Baekdal T.
    Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM, Azorin JM, Despiegel N, Verpillat P.
    Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
    [Abstract] [Full Text] [Related]

  • 10. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P, Legault M.
    Depress Anxiety; 2008 Mar; 25(12):E173-81. PubMed ID: 19006260
    [Abstract] [Full Text] [Related]

  • 11. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
    Olié JP, Tonnoir B, Ménard F, Galinowski A.
    Depress Anxiety; 2007 Mar; 24(5):318-24. PubMed ID: 17041922
    [Abstract] [Full Text] [Related]

  • 12. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG, Schlaepfer TE, Andersen HF, Kilts CD.
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [Abstract] [Full Text] [Related]

  • 13. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
    McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH, EMBOLDEN II (Trial D1447C00134) Investigators.
    J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
    [Abstract] [Full Text] [Related]

  • 14. [Severe forms of depression: the efficacy of escitalopram].
    Spadone C.
    Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
    [Abstract] [Full Text] [Related]

  • 15. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study.
    Pae CU, Kim YJ, Won WY, Kim HJ, Lee S, Lee CU, Lee SJ, Kim DW, Lee C, Min WS, Kim CC, Paik IH, Serretti A.
    Hum Psychopharmacol; 2004 Jan; 19(1):25-9. PubMed ID: 14716708
    [Abstract] [Full Text] [Related]

  • 16. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 17. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence].
    Daléry J, Aubin V.
    Encephale; 2001 Jun; 27(1):71-81. PubMed ID: 11294041
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
    Schmitt L, Tonnoir B, Arbus C.
    Neuropsychobiology; 2006 Jun; 54(4):201-7. PubMed ID: 17337913
    [Abstract] [Full Text] [Related]

  • 19. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
    Pinto C, Trivedi JK, Vankar GK, Sharma PS, Narasimha V.
    J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
    [Abstract] [Full Text] [Related]

  • 20. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P, Andersen HF, Wade A.
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.